11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

Why these comorbidities are tested together

The CSR outline lists "comorbidities (e.g., diabetes, gastrointestinal, cardiovascular disease)" under Domain 2 treatments, and one task asks you to recommend management plans for GI and cardiovascular disease. Both are common in kidney disease, both change nutrient needs, and both interact with potassium, phosphorus and fluid management.

Gastrointestinal comorbidities

Gastroparesis

Diabetic autonomic neuropathy and uremia slow gastric emptying, causing early satiety, bloating, nausea, vomiting and erratic glucose.

• Diet: small, frequent meals; lower fat and lower insoluble fiber; smooth or pureed textures; liquid calories when solids fail. Stay upright after meals.
• Medications: metoclopramide dosing must be reduced in CKD because it accumulates and carries a risk of tardive dyskinesia. The prescriber decides.
• Glucose: match insulin timing to actual absorption; mealtime insulin given after the meal may reduce hypoglycemia.
• Severe cases: consider jejunal feeding or other support when oral intake stays inadequate.

Constipation

Constipation is very common with fluid limits, low fiber intake, inactivity, calcium binders, oral iron and opioids.

• Why it matters: in advanced CKD, the colon excretes more of the daily potassium load. Constipation blocks that route and can raise serum potassium. In PD, a loaded colon can also displace the catheter and impair drainage.
• Diet: add fiber from lower-potassium sources (for example, berries, apples, cabbage, green beans, and oats in portions) and moving fluid allowances toward water.
• Laxatives: polyethylene glycol, lactulose, senna and stool softeners are generally acceptable. Avoid magnesium-based laxatives (magnesium citrate, milk of magnesia) and sodium phosphate enemas or oral solutions, which can cause dangerous hypermagnesemia or hyperphosphatemia and acute phosphate nephropathy.

Diarrhea and malabsorption

Diarrhea (from mycophenolate, infection, diabetic enteropathy or antibiotics) causes losses of potassium, magnesium, bicarbonate and fluid. Monitor electrolytes and adjust restrictions to the labs; a dialysis patient with ongoing diarrhea may need less potassium restriction, not more.

GI bleeding and anemia

Angiodysplasia, ulcers and uremic platelet dysfunction make GI bleeding more common in CKD. Blood in the gut is a protein load that raises BUN, and blood loss drives iron deficiency. Iron-based binders (ferric citrate, sucroferric oxyhydroxide) and oral iron turn stools dark, so teach patients to report black, tarry or sticky stools or other signs of bleeding rather than assuming the binder explains them.

Liver disease with CKD

• Cirrhosis: protein should not be restricted to prevent encephalopathy; hepatology guidance supports normal-to-high protein spread through the day, with a late-evening snack. Sodium restriction manages ascites. Hepatorenal physiology makes fluid balance fragile.
• Hepatitis C: managed under KDIGO's hepatitis C guideline; curative antiviral therapy is used in CKD, dialysis and before transplant.
• Fatty liver disease: follows weight and metabolic management.

Other GI issues

Uremic gastritis, GERD and dysgeusia reduce intake. PD adds early satiety from abdominal fill volume and hernia risk. Pancreatitis can follow severe hypertriglyceridemia.

Cardiovascular comorbidities

Cardiovascular disease is the leading cause of death in dialysis patients, and CKD is itself a major cardiovascular risk factor. Much dialysis death is sudden cardiac death and heart failure rather than classic atherosclerotic events, so volume control, potassium safety and mineral balance matter alongside lipids.

Lipids (KDIGO 2013 Lipid Management in CKD)

Diet still matters for lipids: replace saturated and trans fat with unsaturated fats, add soluble fiber and plant proteins as potassium and phosphorus allow, and limit sugar and alcohol when triglycerides are high. KDOQI 2020 statements on fats:

• a Mediterranean diet may improve lipid profiles in CKD 1–5 not on dialysis and after transplant (3.3.1, 2C);
• in maintenance HD, 1.3–4 g/day of long-chain omega-3 fatty acids may lower triglycerides and LDL (2C) and raise HDL (2D);
• in CKD 3–5, about 2 g/day lowers triglycerides (2C);
• but do not routinely prescribe omega-3s in HD to reduce mortality (2C) or cardiovascular events (2B), and do not prescribe fish oil to improve AV graft or fistula patency.

Blood pressure

• Non-dialysis CKD: KDIGO's 2021 blood-pressure guideline suggests a systolic target below 120 mmHg when tolerated, using standardized office measurement.
• Dialysis: targets rely on dry-weight management. The CMS Measures Assessment Tool (citing KDOQI 2005) lists pre-dialysis BP below 140/90 and post-dialysis below 130/80 mmHg for adults.
• Nutrition levers: sodium restriction (KDOQI <2.3 g/day; KDIGO 2024 <2 g/day), weight control, a DASH-style pattern where potassium allows, limited alcohol and physical activity.

Heart failure

Heart failure with kidney disease (cardiorenal syndrome) requires tight sodium control, a fluid plan coordinated with diuretics or ultrafiltration, attention to potassium when RAAS blockers, mineralocorticoid antagonists or SGLT2 inhibitors are used, and protection against cardiac cachexia. Section 7.3 covers how to prioritize these problems.

Balancing heart-healthy eating with renal limits

"Heart-healthy" handouts often push high-potassium foods, whole grains and dairy in amounts that clash with dialysis limits. Individualize: choose lower-potassium produce and leach where needed, use portion control for whole grains and nuts, prefer fresh unprocessed proteins, and never cut protein below the patient's CKD or dialysis target to lower cholesterol.